Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Pressure Injuries
Interventions: HeelMedix Basic & EHOB Waffle; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 22 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Northfield, Illinois

Conditions: Anxiety, Pain, Nausea, Fatigue, Sleep Disturbance
Interventions: Self-Care Toolkit; Other
Lead sponsor: Samueli Institute for Information Biology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Fort Hood, Texas • San Antonio, Texas

Conditions: Melanoma, Skin Cancer
Interventions: Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin, Dacarbazine, Vinblastine, Adjuvant Therapy; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: celecoxib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2013
U.S. locations: 3
States / cities: Chicago, Illinois • Kansas City, Kansas • Oklahoma City, Oklahoma

Conditions: Breast Imaging, Breast Cancer
Interventions: Not listed
Lead sponsor: Koning Corporation; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: AC682; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 2 more

Conditions: Advanced Solid Tumor, Metastatic Breast Cancer
Interventions: Abraxane, ORIN1001; Drug
Lead sponsor: Orinove, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Gilbert, Arizona • Tucson, Arizona • Burbank, California + 16 more

Conditions: Metastatic Breast Cancer
Interventions: Docetaxel, Erythromycin Breath Test (ERMBT); Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Ductal Carcinoma in Situ
Interventions: Intranasal Oxytocin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: NODULOCYSTIC ACNE
Interventions: Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets; Drug
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more

Conditions: Melanoma Stage III, Melanoma
Interventions: nivolumab, Ipilimumab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 3
States / cities: Durham, North Carolina • Lancaster, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Dermatomyositis, Myositis
Interventions: Empasiprubart IV, Placebo IV; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Oceanside, California • DeBary, Florida • Gainesville, Florida + 6 more

Conditions: Breast Cancer, Perioperative/Postoperative Complications
Interventions: fibrin sealant (Beriplast P, TISSEEL VH), breast reconstruction; Drug · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acne Vulgaris
Interventions: Feedback group, Non Feedback group; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 15 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions: Abemaciclib, Biopsy Procedure, Biospecimen Collection, Copanlisib Hydrochloride, Diagnostic Imaging Testing, Echocardiography Test, Fulvestrant, Multigated Acquisition Scan; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Costa Mesa, California • Orange, California + 8 more

Conditions: Erythema
Interventions: Induced Erythema; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Sunburn, Erythema, Sun Protection
Interventions: Goal attainment; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Fulvestrant, MLN9708; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions: Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor); Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Metastatic Melanoma
Interventions: vemurafenib + HD IL-2; Drug
Lead sponsor: Clinigen, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more

Conditions: Metastatic Melanoma, Metastatic Kidney Cancer
Interventions: Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: BKM120, Fulvestrant, biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Evaluation of Two Heel Protection Devices to Assess Off-loading Via Pressure Mapping.

Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women

Cone Beam CT for Breast Imaging

Genetic Risk: Whether, When, and How to Tell Adolescents

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer

Finasteride Treatment of Severe Nodulocystic Acne

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

UV Exposure Assessed With Wearable Sensor and Sun Protection

Phase I Study of the Combination of MLN9708 and Fulvestrant

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer